Crossover pharmacokinetic study of tobramycin administered for inhalation by PARI eflow rapid electronic nebulizer (no compressor) vs. PARI LC PLUSTM jet nebulizer (with compressor) in cystic fibrosis subjects
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Tobramycin (Primary)
- Indications Pseudomonal infections
- Focus Pharmacokinetics
- Sponsors Novartis
- 23 Jan 2007 New trial record.
- 11 Jan 2007 Biomarkers information updated